Platelet Neutralization Procedure, Plasma
Use
This test aids in the confirmation or exclusion of the presence of a lupus anticoagulant (LAC) inhibitor when used alongside other appropriate coagulation tests. It helps differentiate deficiencies or inhibitors of specific coagulation factors from LAC inhibitors. Particularly, it is useful when the baseline activated partial thromboplastin time (APTT) is significantly prolonged, and inhibition is demonstrated or suggested by a mixing study with normal plasma.
Special Instructions
Not provided.
Limitations
The presence of heparin or specific coagulation factor V inhibitors may lead to false-positive results. It is crucial to consider the results from other coagulation tests like prothrombin time and thrombin time to evaluate potential interfering conditions. Proper specimen collection and handling are vital; errors may cause diagnostic confusion.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Optical Clot-Based)
Biomarkers
Lupus Anticoagulant
Analyte
LOINC Codes
- 103620-1 - LA aPTT screening panel PPP
- 75506-6 - Confirm aPTT
- 103619-3 - aPTT.lupus sens.buffer (LA control) PPP
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Collection involves patient plasma with buffer and PNP platelet reagent. Specimens should be combined and incubated per specific guidelines.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 2 years |